Overview

Full Product Details

9781032338781

Table of Contents

Reviews

This book is an excellent compilation of chapters from a variety of authors coming from pharmaceutical companies, academia, and even one from the food and drug administration (FDA) to inform readers about the current paradigm in oncology clinical trials. The chapters dive much deeper than the standard, parallel, randomized, controlled trials that we may expect in phase III and instead start with phase I development, move into phases II and III, and then consider quality of life (QOL) and regulatory concerns. Thus, reading chronologically, the book offers a generous overview spanning oncology drug development; each chapter, however, could be read in isolation to understand that particular phase of trial design or subject matter. ~Kelley M. Kidwell, Biometrics Journal The book covers all aspects of statistics for clinical oncology, including statistical considerations in phase I oncology trials, response analysis in oncology trials, and statistical measures of interaction for evaluating a predictive biomarker. The book also explores design considerations for phase II oncology clinical trials, precision medicine and its associated challenges, use of adaptive designs in late-stage oncology trials, and safety monitoring. ~Luca Bertolaccini, ISCB

This book is an excellent compilation of chapters from a variety of authors coming from pharmaceutical companies, academia, and even one from the food and drug administration (FDA) to inform readers about the current paradigm in oncology clinical trials. The chapters dive much deeper than the standard, parallel, randomized, controlled trials that we may expect in phase III and instead start with phase I development, move into phases II and III, and then consider quality of life (QOL) and regulatory concerns. Thus, reading chronologically, the book offers a generous overview spanning oncology drug development; each chapter, however, could be read in isolation to understand that particular phase of trial design or subject matter. ~Kelley M. Kidwell, Biometrics Journal The book covers all aspects of statistics for clinical oncology, including statistical considerations in phase I oncology trials, response analysis in oncology trials, and statistical measures of interaction for evaluating a predictive biomarker. The book also explores design considerations for phase II oncology clinical trials, precision medicine and its associated challenges, use of adaptive designs in late-stage oncology trials, and safety monitoring. ~Luca Bertolaccini, ISCB This book is an excellent compilation of chapters from a variety of authors coming from pharmaceutical companies, academia, and even one from the food and drug administration (FDA) to inform readers about the current paradigm in oncology clinical trials. The chapters dive much deeper than the standard, parallel, randomized, controlled trials that we may expect in phase III and instead start with phase I development, move into phases II and III, and then consider quality of life (QOL) and regulatory concerns. Thus, reading chronologically, the book offers a generous overview spanning oncology drug development; each chapter, however, could be read in isolation to understand that particular phase of trial design or subject matter. ~Kelley M. Kidwell, Biometrics Journal The book covers all aspects of statistics for clinical oncology, including statistical considerations in phase I oncology trials, response analysis in oncology trials, and statistical measures of interaction for evaluating a predictive biomarker. The book also explores design considerations for phase II oncology clinical trials, precision medicine and its associated challenges, use of adaptive designs in late-stage oncology trials, and safety monitoring. ~Luca Bertolaccini, ISCB

"""This book is an excellent compilation of chapters from a variety of authors coming from pharmaceutical companies, academia, and even one from the food and drug administration (FDA) to inform readers about the current paradigm in oncology clinical trials. The chapters dive much deeper than the standard, parallel, randomized, controlled trials that we may expect in phase III and instead start with phase I development, move into phases II and III, and then consider quality of life (QOL) and regulatory concerns. Thus, reading chronologically, the book offers a generous overview spanning oncology drug development; each chapter, however, could be read in isolation to understand that particular phase of trial design or subject matter."" ~Kelley M. Kidwell, Biometrics Journal ""The book covers all aspects of statistics for clinical oncology, including statistical considerations in phase I oncology trials, response analysis in oncology trials, and statistical measures of interaction for evaluating a predictive biomarker. The book also explores design considerations for phase II oncology clinical trials, precision medicine and its associated challenges, use of adaptive designs in late-stage oncology trials, and safety monitoring."" ~Luca Bertolaccini, ISCB"

Author Information

Satrajit Roychoudhury is a Senior Director and a member of the Statistical Research and Innovation group in Pfizer Inc. Prior to joining; he was a member of Statistical Methodology and consulting group in Novartis. He has 11 years of extensive experience in working with different phases of clinical trial. His area of research includes early phase oncology trials, survival analysis, model informed drug development, and use of Bayesian methods in clinical trials. He is industry co-chair for the ASA Biopharmaceutical Section Regulatory-Industry Workshop and has provided statistical training in major conferences including the Joint Statistical Meetings, ASA Biopharmaceutical Section Regulatory-Industry Workshop, and ICSA Applied Statistics Symposium. Soumi Lahiri has 12 years of extensive experience in working different therapeutic areas. She is the former Director of Biostatistics in Clinical Oncology, GlaxoSmithKline. She has also worked in the oncology division of Novartis Pharmaceutical Company for two years. She is an active member of the ASA Biopharmaceutical section and former chair of the membership committee.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available